newsfilter
← Latest News
GlobeNewswire·

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On June 1, 2026, Orchestra BioMed's Compensation Committee granted stock options for 85,500 shares to five newly hired employees.
  • The awards were issued under the 2025 New Hire Inducement Plan to induce employment in compliance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option grant will vest over a four-year period.
  • The company is accelerating two flagship candidates, AVIM Therapy & Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), through strategic partnerships & pivotal clinical trials.
  • AVIM Therapy is a bioelectronic hypertension treatment developed with Medtronic for pacemaker-indicated patients, holding FDA Breakthrough Device Designation.
  • Virtue SAB is a non-coated drug delivery balloon system for atherosclerotic artery disease, also holding FDA Breakthrough Device Designation for specific indications.